CRIS Curis Inc.

0  0%
Previous Close 1.61
Price To Book -3.93
Market Cap 53,372,756
Shares 33,150,780
Volume 0
Short Ratio
Av. Daily Volume 143,654

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due mid-2019.
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 mesothelioma data due 2H 2019.
Solid Tumors and Lymphomas
Approved January 30, 2012.
Basal Cell Carcinoma
Phase 1b initial data in DH/DE DLBCL 2H 2019.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
  2. Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT
  3. Curis: 1Q Earnings Snapshot
  4. Curis Reports First Quarter 2019 Financial Results
  5. Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019
  6. Curis Completes Mesothelioma Enrollment in CA-170 Study
  7. Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop
  8. Curis Regains Compliance with Nasdaq Continued Listing Requirements
  9. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  10. Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT
  11. Curis Reports Fourth Quarter and Year-End 2018 Financial Results
  12. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  13. What's Driving The Rally In Microcap Biotech Curis?
  14. Biotech News: Why Curis Stock Is Soaring Today
  15. Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties
  16. Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million
  17. Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019
  18. Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference
  19. Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference